Gemzar (gemcitabine)

January 30, 2017

Evidence Supporting Benefit of Second-line Treatment for Mesothelioma Weak, Clinical Trials Needed

News

There is no clear evidence supporting the benefits of second-line active treatments for patients with malignant pleural mesothelioma (MPM) whose first line of treatment failed. This is according to an ... Read more

January 3, 2017

Gene Variations May Help Predict Survival in Mesothelioma Patients Receiving Platinum-based Chemotherapy, Study Finds

News

Variations in the immune-system-related FAS ligand (FASL) gene may help predict how long a malignant pleural mesothelioma patient who received platinum-based chemotherapy can survive without the disease progressing. A study in Egypt showed ... Read more

September 23, 2016

New Bromodomain Inhibitor Shows Promise in Treating Malignant Pleural Mesothelioma

News

A new bromodomain and extraterminal (BET) inhibitor, OTX015, may be a promising approach to treat malignant pleural mesothelioma (MPM), according to a recent study published in the International Journal of ... Read more